Patents by Inventor Carey Horchler

Carey Horchler has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20080318943
    Abstract: This invention relates to novel compounds having the structural formula I below: and their pharmaceutically acceptable salts, tautomers or in vivo-hydrolysable precursors, compositions and methods of use thereof, wherein R1, R2, R3, R4, R5, and R6 are defined in the specification. These novel compounds provide a treatment or prophylaxis of anxiety disorders, schizophrenia, cognitive disorders, and/or mood disorders.
    Type: Application
    Filed: June 18, 2008
    Publication date: December 25, 2008
    Applicant: ASTRAZENECA AB
    Inventors: Hui-Fang Chang, Marc Chapdelaine, Bruce Thomas Dembofsky, Keith John Herzog, Carey Horchler, Richard Jon Schmiesing
  • Publication number: 20080113983
    Abstract: Acetylcholine receptor ligands of formula I wherein A, Ar1 and Ar2 are as described in the specification, diastereoisomers, enantiomers, pharmaceutically-acceptable salts, methods of making, pharmaceutical compositions containing and methods for using the same.
    Type: Application
    Filed: December 13, 2005
    Publication date: May 15, 2008
    Applicant: AstraZeneca AB
    Inventors: Marc Chapdelaine, Hui-Fang Chang, Keith J. Herzog, Carey Horchler, Eifion Phillips
  • Publication number: 20080076759
    Abstract: Provided herein is a compound having the formula (I): Wherein said compounds are useful for the treatment of psychiatric disorders including but not limited to depression, generalized anxiety, eating disorders, dementia, panic disorder, and sleep disorders. The compounds may also be useful in the treatment of gastrointestinal disorders, cardiovascular regulation, motor disorders, endocrine disorders, vasospasm and sexual dysfunction. The compounds are 5HT1B and 5HT1D antagonists.
    Type: Application
    Filed: September 28, 2007
    Publication date: March 27, 2008
    Applicant: AstraZeneca AB
    Inventors: Edward Pierson, Daniel Sohn, Markus Haeberlein, Timothy Davenport, Marc Chapdelaine, Carey Horchler, John McCauley
  • Patent number: 7285662
    Abstract: Provided herein is a compound having the formula (I): Wherein said compounds are useful for the treatment of psychiatric disorders including but not limited to depression, generalized anxiety, eating disorders, dementia, panic disorder, and sleep disorders. The compounds may also be useful in the treatment of gastrointestinal disorders, cardiovascular regulation, motor disorders, endocrine disorders, vasospasm and sexual dysfunction. The compounds are 5HT1B and 5HT1D antagonists.
    Type: Grant
    Filed: April 18, 2005
    Date of Patent: October 23, 2007
    Assignee: AstraZeneca AB
    Inventors: Edward Pierson, Daniel Sohn, Markus Haeberlein, Timothy Davenport, Marc Chapdelaine, Carey Horchler, John P. McCauley
  • Publication number: 20060178372
    Abstract: Provided herein is a compound having the formula (I): Wherein said compounds are useful for the treatment of psychiatric disorders including but not limited to depression, generalized anxiety, eating disorders, dementia, panic disorder, and sleep disorders. The compounds may also be useful in the treatment of gastrointestinal disorders, cardiovascular regulation, motor disorders, endocrine disorders, vasospasm and sexual dysfunction. The compounds are 5HT1B and 5HT1D antagonists.
    Type: Application
    Filed: April 4, 2006
    Publication date: August 10, 2006
    Applicant: AstraZeneca AB
    Inventors: Markus Haeberlein, Daniel Sohn, Marc Chapdelaine, Timothy Davenport, Carey Horchler, Edward Pierson, John McCauley
  • Patent number: 7045514
    Abstract: Provided herein is a compound having the formula (I): Wherein said compounds are useful for the treatment of psychiatric disorders including but not limited to depression, generalized anxiety, eating disorders, dementia, panic disorder, and sleep disorders. The compounds may also be useful in the treatment of gastrointestinal disorders, cardiovascular regulation, motor disorders, endocrine disorders, vasospasm and sexual dysfunction. The compounds are 5HT1B and 5HT1D antagonists.
    Type: Grant
    Filed: July 12, 2004
    Date of Patent: May 16, 2006
    Assignee: AstraZeneca AB
    Inventors: Edward Pierson, Daniel Sohn, Markus Haeberlein, Timothy Davenport, Marc Chapdelaine, Carey Horchler, John P. McCauley
  • Patent number: 7026314
    Abstract: Provided herein is a compound of the formula (I) wherein said compound is useful for the treatment of psychiatric disorders including but not limited to depression, generalized anxiety, eating, disorders, dementia, panic disorder, and sleep disorders. The compounds may also be useful in the treatment of gastrointestinal disorders, cardiovascular regulation, motor disorders, endocrine disorders, vasospasm and sexual dysfunction. The compounds are 5HT1B antagonists. Also provided herein are processes for making compounds of Formula (I) and intermediate compounds.
    Type: Grant
    Filed: January 15, 2002
    Date of Patent: April 11, 2006
    Assignee: AstraZeneca AB
    Inventors: Marc Chapdelaine, Timothy Davenport, Markus Haeberlein, Carey Horchler, John McCauley, Edward Pierson, Daniel Sohn
  • Publication number: 20060019947
    Abstract: Provided herein is a compound of the formula (I) wherein said compound is useful for the treatment of psychiatric disorders including but not limited to depression, generalized anxiety, eating, disorders, dementia, panic disorder, and sleep disorders. The compounds may also be useful in the treatment of gastrointestinal disorders, cardiovascular regulation, motor disorders, endocrine disorders, vasospasm and sexual dysfunction. The compounds are 5HT1B in antagonists. Also provided herein are processes for making compounds of Formula (I) and intermediate compounds.
    Type: Application
    Filed: September 16, 2005
    Publication date: January 26, 2006
    Inventors: Marc Chapdelaine, Timothy Davenport, Markus Haeberlein, Carey Horchler, John McCauley, Edward Pierson, Daniel Sohn
  • Publication number: 20050182050
    Abstract: Provided herein is a compound having the formula (I): Wherein said compounds are useful for the treatment of psychiatric disorders including but not limited to depression, generalized anxiety, eating disorders, dementia, panic disorder, and sleep disorders. The compounds may also be useful in the treatment of gastrointestinal disorders, cardiovascular regulation, motor disorders, endocrine disorders, vasospasm and sexual dysfunction. The compounds are 5HT1B and 5HT1D antagonists.
    Type: Application
    Filed: April 18, 2005
    Publication date: August 18, 2005
    Applicant: AstraZeneca AB
    Inventors: Edward Pierson, Daniel Sohn, Markus Haeberlein, Timothy Davenport, Marc Chapdelaine, Carey Horchler, John McCauley
  • Publication number: 20050096312
    Abstract: Provided herein is a compound having the formula (I), (R2 is typically a tertiary nitrogen atom, being either alkyl-substituted or member of a heterocyclic ring; R7 is typically a monocyclic or bicyclic aromatic ring or a heterocyclic ring) wherein said compounds are useful for the treatment of psychiatric disorders including but not limited to depression, generalized anxiety, eating disorders, dementia, panic disorder, and sleep disorders. The compounds may also be useful in the treatment of gastrointestinal disorders, cardiovascular regulation, motor disorders, endocrine disorders, vasospasm and sexual dysfunction. The compounds are 5HT1B and 5HT1D antagonists.
    Type: Application
    Filed: November 1, 2002
    Publication date: May 5, 2005
    Inventors: Markus Haeberlein, Daniel Sohn, Marc Chapdelaine, Timothy Davenport, Carey Horchler, Edward Pierson, John McCauley
  • Publication number: 20050085457
    Abstract: Provided herein is a compound having the formula (I) (R2 is typically a tertiary nitrogen atom, being either alkyl-substituted or member of q heterocyclic ring; R7 is typically a monocyclic or bicyclic aromatic ring or a heterocyclic ring) wherein said compounds are useful for the treatment of psychiatric disorders including but not limited to depression, generalized anxiety, eating disorders, dementia, panic disorder, and sleep disorders. The compounds may also be useful in the treatment of gastrointestinal disorders, cardiovascular regulation, motor disorders, endocrine disorders, vasospasm and sexual dysfunction. The compounds are 5HT1B and 5HT1D antagonists.
    Type: Application
    Filed: November 1, 2002
    Publication date: April 21, 2005
    Inventors: Markus Haeberlein, Daniel Sohn, Marc Chapdelaine, Timothy Davenport, Carey Horchler, Edward Pierson, John McCauley
  • Publication number: 20050070544
    Abstract: Compounds are disclosed according to structural diagram (1), wherein R1, A, D and E are as defined in the specification. Also disclosed are methods for the treatment of pain and pharmaceutical compositions comprising a pain-ameliorating effective amount of a compound in accord with structural diagram (1).
    Type: Application
    Filed: September 28, 2001
    Publication date: March 31, 2005
    Inventors: Megan Murphy, Wenhua Xiao, Dean Brown, Rebecca Urbanek, Frances MClaren, Edward Vacek, Thomas Bare, Carey Horchler, Christine Barlaam, Gary Steelman, Vernon Alford
  • Publication number: 20050009818
    Abstract: Provided herein is a compound having the formula (I): Wherein said compounds are useful for the treatment of psychiatric disorders including but not limited to depression, generalized anxiety, eating disorders, dementia, panic disorder, and sleep disorders. The compounds may also be useful in the treatment of gastrointestinal disorders, cardiovascular regulation, motor disorders, endocrine disorders, vasospasm and sexual dysfunction. The compounds are 5HT1B and 5HT1D antagonists.
    Type: Application
    Filed: July 12, 2004
    Publication date: January 13, 2005
    Inventors: Edward Pierson, Daniel Sohn, Markus Haeberlein, Timothy Davenport, Marc Chapdelaine, Carey Horchler, John McCauley
  • Patent number: 6812225
    Abstract: Provided herein is a compound having the formula (I): Wherein said compounds are useful for the treatment of psychiatric disorders including but not limited to depression, generalized anxiety, eating disorders, dementia, panic disorder, and sleep disorders. The compounds may also be useful in the treatment of gastrointestinal disorders, cardiovascular regulation, motor disorders, endocrine disorders, vasospasm and sexual dysfunction. The compounds are 5HT1B and 5HT1D antagonists.
    Type: Grant
    Filed: January 16, 2002
    Date of Patent: November 2, 2004
    Assignee: AstraZeneca AB
    Inventors: Edward Pierson, Daniel Sohn, Markus Haeberlein, Timothy Davenport, Marc Chapdelaine, Carey Horchler, John P. McCauley
  • Publication number: 20040110745
    Abstract: Provided herein is a compound represented by the Formula (I) wherein said compounds are useful for the treatment of migraine. Also provided are processes for the preparation of compounds of Formula (I) and intermediates.
    Type: Application
    Filed: July 16, 2003
    Publication date: June 10, 2004
    Inventors: Marc Chapdelaine, Timothy Davenport, Markus Haeberlein, Carey Horchler, John McCauley, Edward Pierson, Daniel Sohn
  • Publication number: 20040087575
    Abstract: Provided herein is a compound of the formula (I) wherein said compound is useful for the treatment of psychiatric disorders including but not limited to depression, generalized anxiety, eating, disorders, dementia, panic disorder, and sleep disorders. The compounds may also be useful in the treatment of gastrointestinal disorders, cardiovascular regulation, motor disorders, endocrine disorders, vasospasm and sexual dysfunction. The compounds are 5HT1B antagonists. Also provided herein are processes for making compounds of Formula (I) and intermediate compounds.
    Type: Application
    Filed: July 16, 2003
    Publication date: May 6, 2004
    Inventors: Marc Chapdelaine, Timothy Davenport, Markus Haeberlein, Carey Horchler, John McCauley, Edward Pierson, Daniel Sohn
  • Publication number: 20040082591
    Abstract: Provided herein is a compound having the formula (I) wherein said compounds are useful for the treatment of psychiatric disorders including but not limited to depression, generalized anxiety, eating disorders, dementia, panic disorder, and sleep disorders. The compounds may also be useful in the treatment of gastrointestinal disorders, cardiovascular regulation, motor disorders, endocrine disorders, vasospasm and sexual dysfunction. The compounds are 5HT1B and 5HT1D antagonists.
    Type: Application
    Filed: July 16, 2003
    Publication date: April 29, 2004
    Inventors: Marc Chapdelaine, Timothy Davenport, Markus Haeberlein, Carey Horchler, John McCauley, Edward Pierson, Daniel Sohn
  • Publication number: 20030013708
    Abstract: Provided herein is a compound having the formula (I): 1
    Type: Application
    Filed: January 16, 2002
    Publication date: January 16, 2003
    Inventors: Edward Pierson, Daniel Sohn, Markus Haeberlein, Timothy Davenport, Marc Chapdelaine, Carey Horchler, John P. McCauley